Inflation Reduction Act — Climate, Clean Energy & Health Provisions

Current status: The IRA's residential energy tax credits (§ 25C and § 25D) ended December 31, 2025 under the One Big Beautiful Bill Act (OBBBA, HR1, 119th Congress). Both credits are no longer available for property placed in service after that date. The IRA's business-side credits (PTC/ITC under §§ 45, 48, 45Y, 48E) and EV credits remain on the books, though OBBBA also modified eligibility for several of these — verify current terms before relying on any IRA-era credit.

The Inflation Reduction Act of 2022 (IRA) (Pub. L. 117-169) was the most significant federal climate and clean energy legislation in American history — investing approximately $370 billion in clean energy tax credits, grants, and loans over 10 years. It is also the most significant healthcare cost-reduction law since the ACA — enabling Medicare drug price negotiation for the first time and extending ACA premium subsidies. Passed through budget reconciliation (Senate 51-50 with VP tiebreaker, House 220-207), the IRA relied primarily on tax incentives rather than mandates. Many of those incentives were modified or rescinded by OBBBA (2025), particularly on the residential side — both home energy credits (§ 25C Energy Efficient Home Improvement and § 25D Residential Clean Energy) ended for property placed in service after December 31, 2025. Surviving climate/energy provisions include the Production Tax Credit (PTC) and Investment Tax Credit (ITC) for utility-scale renewable energy, the clean vehicle credit (up to $7,500 for new EVs, $4,000 for used, subject to OBBBA-tightened eligibility), environmental justice funding ($60 billion for disadvantaged communities), and incentives for domestic clean energy manufacturing (batteries, solar panels, critical minerals). Key health provisions remain intact: Medicare can negotiate prices on certain high-cost drugs (starting with 10 drugs in 2026, expanding to 20 by 2029), a $2,100 annual cap on Medicare Part D out-of-pocket costs (effective 2026), insulin capped at $35/month for Medicare beneficiaries, and ACA premium subsidies extended through 2025 (further extensions debated).

Current Law (2026)

Legal Authority

• Inflation Reduction Act of 2022 (Pub. L. 117-169, signed August 16, 2022)
• 26 U.S.C. § 30D — Clean vehicle credit (new EVs)
• 26 U.S.C. § 25E — Previously-owned clean vehicle credit (used EVs)
• 26 U.S.C. § 25C — Energy efficient home improvement credit
• 26 U.S.C. § 45 — Renewable electricity production credit (PTC)
• 26 U.S.C. § 48 — Energy investment credit (ITC)
• 42 U.S.C. § 1395w-111 — Medicare Part D drug price negotiation

How It Works

The IRA's core energy provisions center on two foundational tax credits: the Production Tax Credit (PTC) — approximately $0.028/kWh in 2026 for wind, solar, geothermal, and hydropower — and the Investment Tax Credit (ITC) at a 30% base rate for solar, battery storage, and qualifying technologies. Both credits carry bonus adders of +10% for projects in energy communities (former fossil fuel areas), +10% for meeting domestic content requirements (U.S.-made steel, iron, and manufactured components), and +10–20% for low-income community or Indian land projects. Starting in 2025, technology-neutral clean electricity credits replace the technology-specific PTC/ITC — any zero-emission generation technology qualifies — phasing out once U.S. power sector greenhouse gas emissions fall below 25% of 2022 levels. The clean vehicle credit under § 30D offers up to $7,500 for EVs and plug-in hybrids assembled in North America with battery components and critical minerals meeting domestic content requirements, split $3,750 for minerals and $3,750 for battery components; income limits apply ($150,000 AGI single, $300,000 MFJ), and starting 2024 the credit is available as a point-of-sale discount. The used EV credit under § 25E offers up to $4,000 or 30% of price (whichever is less) for used EVs priced at $25,000 or less, with lower income limits ($75,000 single, $150,000 MFJ).

For homeowners, the IRA established two residential energy credits that both ended December 31, 2025 under OBBBA. While active, the § 25C credit provided up to $3,200/year — $2,000 for heat pumps, heat pump water heaters, and biomass stoves; $1,200 for insulation, windows, doors, and building envelope improvements; and $150 for home energy audits — covering 30% of costs up to those annual limits. The separate § 25D Residential Clean Energy Credit covered solar panels, battery storage, geothermal heat pumps, and small wind at 30% with no annual cap. As of 2026, no new credit is available for property placed in service or expenditures made after 2025-12-31, though unused 2025 § 25D credit can still carry forward into later tax years. On the healthcare side, the IRA made history by allowing Medicare to negotiate drug prices for the first time — starting with 10 drugs in 2026 (including Eliquis, Jardiance, Xarelto, and Januvia), expanding to 15 in 2027–2028 and 20 in 2029+; the first round achieved average price reductions of 38–79% from list prices, and manufacturers who refuse to negotiate face an excise tax of up to 95% of U.S. sales. The $2,100 annual Medicare Part D out-of-pocket cap (effective 2026) and the $35/month insulin cap provide additional direct financial relief to seniors.

How It Affects You

If you're a homeowner: The IRA's two residential energy credits — § 25C (Energy Efficient Home Improvement) and § 25D (Residential Clean Energy) — both ended December 31, 2025 under OBBBA. As of 2026, no new federal credit is available for property installed or expenditures made after that date. If you completed qualifying work in 2025, you can still claim § 25C (up to $3,200 across the heat-pump and envelope sub-caps) on your 2025 return; unused § 25D credit can carry forward into 2026 and later returns until exhausted. For weatherization or solar work in 2026 and beyond, focus on state rebates, utility programs, and any remaining local incentives rather than federal credits. Some states also funded Home Energy Rebate Programs through DOE pass-throughs — check your state's energy office at energy.gov/scep/home-energy-rebates-programs. For 2025-return filing, claim § 25C and § 25D on IRS Form 5695; § 25C 2025 claims also require the qualified manufacturer ID (QMID) on specified property.

If you're buying an electric vehicle: The § 30D New Clean Vehicle Credit offers up to $7,500 for new EVs, but eligibility is tightly conditioned. Your MAGI must be under $150,000 (single), $225,000 (head of household), or $300,000 (married filing jointly) — and this is measured in the current or prior year, whichever is lower. The vehicle must have a final assembly in North America (many popular EVs qualify; some Japanese and Korean models don't). MSRP cap: $80,000 for pickups, SUVs, and vans; $55,000 for cars and other vehicles. The $4,000 Used Clean Vehicle Credit (§ 25E) applies to EVs under $25,000 with a lower income threshold ($75K/$112.5K/$150K). As of 2024, both credits can be taken as a point-of-sale discount through participating dealers — you get the cash at the time of purchase rather than waiting for your tax return. Check current vehicle eligibility at fueleconomy.gov/feg/tax-credits.do and at afdc.energy.gov/vehicles/search/results — eligibility changes as manufacturers update their battery sourcing; verify at the time of purchase, not months earlier. The Trump administration's 2025 executive orders directed EPA and Treasury to review EV incentives; the § 30D credit remains statutory but implementation guidance may change.

If you're a Medicare beneficiary: The IRA's health provisions deliver real dollar savings on drug costs, with the largest changes effective in 2025-2026. Part D out-of-pocket maximum: capped at $2,100/year starting in 2026 — before the IRA, there was no OOP cap, and patients with high-cost drugs could pay tens of thousands annually. Insulin: capped at $35/month per prescription for all Medicare Part D beneficiaries, regardless of plan or formulary. Drug price negotiation: the first 10 drugs negotiated by CMS under the IRA's new authority take effect in 2026, with negotiated prices estimated to be 38-79% below list prices. The negotiated drugs include popular treatments for blood thinners, diabetes, and other common conditions — CMS publishes the full list and negotiated prices at cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices. ACA marketplace subsidies: the IRA extended enhanced premium tax credits through 2025; if Congress doesn't extend them again, premiums will rise significantly in 2026 — this is an active legislative question as of mid-2026.

If you're developing, financing, or investing in clean energy projects: The IRA's energy title is the most significant federal clean energy investment in U.S. history — approximately $370 billion over 10 years in tax credits and direct spending. For project finance, the key credits are the Production Tax Credit (§ 45) and Investment Tax Credit (§ 48/48E), both extended through at least 2032 and expanded to cover a broader technology set. The domestic content bonus (IRC § 45Y/48E) adds 10% to the credit rate for projects using steel, iron, and manufactured components from U.S. sources. The energy communities bonus adds 10% for projects in communities affected by fossil fuel industry decline. The direct pay provision (§ 6417) allows tax-exempt entities (municipalities, nonprofits, tribal governments) to receive these credits as cash payments rather than tax offsets — a structural shift that opened clean energy financing to entities that previously couldn't monetize the credits. Track IRA credit implementation guidance from Treasury at irs.gov/credits-deductions/businesses and the Clean Energy Investment Monitor at cleaninvestmentmonitor.org for aggregate deployment data.

State Variations

The IRA is federal law, but states affect implementation:

• State incentives stack with federal credits — many states offer their own EV rebates, solar incentives, and energy efficiency programs
• State electricity markets determine how renewable energy credits affect consumer prices
• State building codes affect which energy efficiency improvements qualify
• Some states have enacted their own climate legislation that complements the IRA (California, New York, Massachusetts)

Implementing Regulations

• 26 CFR § 1.30D — IRS clean vehicle credit (EV tax credit) regulations (eligibility, domestic content requirements, income limits, and point-of-sale transfer procedures)
• 26 CFR §§ 1.45Y, 1.45Z — Clean electricity production and investment credit regulations (technology-neutral credits applicable to zero-emission electricity generation, phase-out triggers, and bonus adder requirements)
• 40 CFR Part 60 Subpart OOOOb/c — EPA methane emission standards for new and existing oil and gas operations (IRA-funded enforcement and "Super Emitter" response program)
• 42 CFR Part 423 — CMS Medicare Part D drug price negotiation program (IRA drug pricing provisions, negotiation procedures, maximum fair price determinations, and manufacturer compliance requirements)

Pending Legislation

IRA implementation and potential repeal/modification provisions appear in reconciliation and energy legislation in the 119th Congress. See Clean Energy Tax Credits for related legislative activity.

Recent Developments

Trump administration clawback attempts (2025–2026): The Trump administration sought to impound, pause, or claw back unspent IRA clean energy grant funds — particularly the $27 billion Greenhouse Gas Reduction Fund (including the "Green Bank" program) and climate-related infrastructure grants. DOE and EPA paused grant disbursements under several programs pending review. Federal courts issued preliminary injunctions blocking some grant clawbacks, finding that the administration lacked statutory authority to withhold funds already committed by Congress. The litigation is ongoing as of 2026.

Tax credit continuity post-OBBBA (2025): OBBBA (HR1, 119th Congress) made significant changes to the IRA's tax-credit package. The residential energy credits (§ 25C and § 25D) were terminated for property placed in service or expenditures made after December 31, 2025 — both are no longer available in 2026. The EV credits (§ 30D and § 25E) were modified — income limits tightened, domestic content requirements strengthened, and several bonus adders changed — though both credits remained on the books at the start of 2026. The utility-scale credits (PTC under § 45, ITC under § 48, technology-neutral § 45Y/48E) survived in modified form. Buyers, homeowners, and businesses should verify current eligibility under the post-OBBBA rules; the legal text was significantly rewritten by the 2025 reconciliation legislation, and IRS implementation guidance for the modified provisions is still developing as of mid-2026.

Medicare drug price negotiations: The first 10 negotiated drug prices took effect January 2026 — covering major drugs for blood thinners, diabetes, blood cancer, and heart failure. CMS projects $6 billion in savings in the first year of negotiated prices. The second round of negotiations (15 drugs) is underway. Pharmaceutical companies continue to challenge the program in court, arguing compelled negotiation is unconstitutional, but courts have largely upheld the program so far.

Clean energy investment: The IRA triggered over $300 billion in announced U.S. clean energy manufacturing and deployment by 2025. Domestic semiconductor, solar panel, battery, and EV manufacturing expansions were driven in part by IRA domestic content bonuses. Some projects paused amid tariff uncertainty and credit modifications, but the scale of investment suggests the IRA's economic footprint will persist even if individual credits are modified.